<DOC>
	<DOCNO>NCT02320656</DOCNO>
	<brief_summary>HEMATO-BIO-IPC-2013-015 monocenter prospective longitudinal study . Our aim define predictive clinical biological factor acute leukemia , myelodysplastic syndrome myeloproliferative disorder use genomics , genetics epigenetics , vitro vivo drug sensitivity study , translational immonulogy immunomonitoring study . HEMATO-BIO primary outcome measure identify molecular , genomic epigenetic , pharmacologic immunophenotypic alteration acute leukemia , myelodysplastic syndrome myeloproliferative disorder collect , diagnosis and/or complete remission and/or relapse : - tumor sample : marrow aspiration , blood sampling . - non-tumor sample : skin biopsy , buccal swab . 300 patient treated cancer center .</brief_summary>
	<brief_title>Predictive Clinical Biological Parameters Acute Leukemia , Myelodysplastic Syndromes Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<criteria>acute leukemia , myelodysplastic syndrome myeloproliferative disease age &gt; 18 affiliated French Social Security Systm sign informed consent emergency patient deprive liberty place authority tutor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>